- |||||||||| gruticibart (AB023) / Bayer, Aronora
Journal: Factor XI Inhibition With Heparin Reduces Clot Formation in Simulated Pediatric Extracorporeal Membrane Oxygenation. (Pubmed Central) - Dec 4, 2023 A roller-pump circuit circulated either 0.5 U/ml of unfractionated heparin alone or in combination with the anti-FXI immunoglobulin G (IgG) (AB023) for 6 hours or until clot formation caused device failure...AB023 plus heparin significantly reduced peak thrombin compared to heparin alone (123 vs. 217?nM; p < 0.01). Inhibition of contact pathway activation of FXI may be an effective adjunct to anticoagulation in extracorporeal life support.
- |||||||||| gruticibart (AB023) / Bayer, Aronora, GS-607601 / Gilead
Journal: SPECT Imaging of Lysyl Oxidase-like 2 in a Model of Idiopathic Pulmonary Fibrosis. (Pubmed Central) - Jun 12, 2023 In conclusion, we report the first radioimmunotracer targeting the protein LOXL2 for nuclear imaging of IPF. The tracer showed promising results in a preclinical model of bleomycin-induced pulmonary fibrosis, with high lung uptake in fibrotic areas, and accounted for the antifibrotic activity of nintedanib.
- |||||||||| gruticibart (AB023) / Bayer, Aronora
CONTACT FACTOR XI INHIBITION IN A SIMULATED ECMO CIRCUIT WITH HUMAN WHOLE BLOOD () - Jan 25, 2023 - Abstract #SCCM2023SCCM_1270; Inhibition of contact pathway activation of Factor XI may be an effective adjunct to decrease systemic anticoagulation of extracorporeal life support. Novel anticoagulants would decrease cost, complications, and barriers to use of lifesaving ECMO.
- |||||||||| gruticibart (AB023) / Bayer, Aronora, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Cancer Patients Undergoing Central Line Placement: A Phase 2 Clinical Trial (291-292 (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_3522; Nine patients in the interventional cohort received AB023, 8 of which underwent surveillance ultrasound, and 10 patients in the control cohort underwent surveillance ultrasound (Table 2). Malignancies included pancreatic cancer (4/11), colorectal cancer (3/11), and lymphoma (2/11) in the interventional study, and lymphoma (4/11) colorectal cancer (3/11), and head and neck cancer (3/11) in the control study.
- |||||||||| Clinical, Journal: The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials. (Pubmed Central) - Dec 20, 2019
Other benefits of some of these drugs include once-monthly dosing and safety in patients with renal or hepatic impairment, while others offer quickly metabolized parenteral options, thus providing more convenient and widely available anticoagulation options. Though still far from the marketplace, drugs targeting FXI and FXII have the potential to usher in a new era of anticoagulation therapy.
- |||||||||| gruticibart (AB023) / Bayer, Aronora
Trial completion, Trial completion date, Trial primary completion date: Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects (clinicaltrials.gov) - Feb 22, 2018 P1, N=21, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jan 2018 --> Jan 2018
- |||||||||| gruticibart (AB023) / Bayer, Aronora
Enrollment closed: Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects (clinicaltrials.gov) - Jan 10, 2018 P1, N=21, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jan 2018 --> Jan 2018 Recruiting --> Active, not recruiting
- |||||||||| gruticibart (AB023) / Bayer, Aronora
Enrollment open, Trial primary completion date: Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects (clinicaltrials.gov) - May 24, 2017 P1, N=21, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2017 --> Nov 2017
|